Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05955040 · ClinicalTrials.gov registry record · Phase 2
Treatment of Elevated Blood Pressures in Early Pregnancy
A Phase 2 study, sponsored by Marshall University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05955040 is a Phase 2 study that was terminated before completion, run by Marshall University. The registered enrollment target is 2 participants.
The verdict
NCT05955040, a Phase 2 study, was terminated before completion, sponsored by Marshall University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a randomized controlled trial comparing the outcomes of treatment and non-treatment of elevated blood pressures in early pregnancy.
Interventions
- DRUG Labetalol
- DRUG Nifedipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05955040
The ClinicalTrials.gov registry entry for NCT05955040 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marshall University, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Labetalol is the first listed.
NCT05955040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05955040 about?
NCT05955040 is a clinical study titled "Treatment of Elevated Blood Pressures in Early Pregnancy". This is a randomized controlled trial comparing the outcomes of treatment and non-treatment of elevated blood pressures in early pregnancy.
What is the current status of trial NCT05955040?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2023-07-11. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT05955040?
The interventions under investigation include: Labetalol (DRUG), Nifedipine (DRUG).
Who is sponsoring clinical trial NCT05955040?
This trial is sponsored by Marshall University, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.